DVA

Business Profile & Competitive Position

DaVita Inc. sits in the Healthcare sector, specifically the Medical - Care Facilities industry. It is one of the largest U.S. providers of kidney dialysis services for patients with chronic kidney failure and end-stage kidney disease. As of December 31, 2025, the company operated 2,657 outpatient dialysis centers in the United States serving roughly 200,500 patients, plus another 585 outpatient centers across 14 countries serving approximately 94,500 patients.

The numbers point to a scale-driven business with a narrow but real margin profile. Net margin is 6.0%, which is modest for a healthcare services operator, and the company’s 10-K notes that U.S. dialysis represented about 86% of consolidated revenue and that nearly all non-hospital dialysis profit came from commercial payors. That concentration means the U.S. commercial insurance book is the true profit engine, even though Medicare typically dominates patient volume. Return on equity is -123.6%, a figure that says more about capital structure than operating health: aggressive buybacks and leverage can push equity into negative territory, making ROE an unreliable moat signal here. The more durable competitive argument is operational scale and quality track record; DaVita has led CMS’s Quality Incentive Program for 11 reporting years and the Five-Star Quality Rating System for 10 reporting years.

Financial Posture

DaVita currently carries an $11.5 billion market capitalization and trades at a price-to-earnings ratio of 15.5. The stock’s beta is 0.80, implying lower volatility than the broad market, consistent with a stable, recurring-revenue care-facility business. Net margin is 6.0%, which supports the P/E but also shows limited after-tax cushion relative to revenue.

At the current snapshot price of $179.83501, the stock is below its 50-day exponential moving average of $185.69 and the RSI is 48.6, neither overbought nor deeply oversold. The standout financial oddity is the -123.6% ROE. When combined with headlines describing DaVita as a “buyback machine,” the negative ROE likely reflects shareholder distributions and leverage that have shrunk the equity base rather than a current loss-making operation. That distinction matters: the business is profitable on a net-margin basis, but the balance sheet is heavily geared, so credit, interest-rate, and buyback-policy dynamics deserve as much attention as operating metrics.

Strategic Priorities & Outlook

DaVita’s most recent 10-K frames the near-term agenda around three operational goals. First, the company wants to “reimagine” kidney care to be more preventative, better integrated, outcome-focused, lower-cost, and personalized at scale. Second, it is building integrated care capabilities across the full renal continuum, from chronic kidney disease through end-stage kidney disease to kidney transplant. Third, it is supporting CMS’s Comprehensive Kidney Care Contracting model, which aims to delay disease progression, promote home dialysis when appropriate, and create incentives for transplants.

Those priorities are reflected in the current business mix. U.S. dialysis is still the dominant revenue source at roughly 86% of consolidated revenue, so the near-term strategic push is largely about expanding margins and patient outcomes inside the core American dialysis footprint rather than diversifying away from it. International operations remain a smaller piece; with 585 centers in 14 countries and about 94,500 patients, overseas growth is a real secondary channel but not yet an equal revenue contributor. The emphasis on quality scores also matters commercially: DaVita’s 11-year leadership in CMS’s Quality Incentive Program and 10-year leadership in the Five-Star system can influence patient referrals, payer contracting, and CMS bonus payments.

Macro & Geopolitical Exposure

As a Medical - Care Facilities operator, DaVita is exposed to the macro forces that shape the broader healthcare-services sector rather than to commodity cycles or discretionary consumer demand. Reimbursement policy is the headline risk: Medicare and Medicaid rates set by CMS directly affect dialysis economics because the Medicare program covers most end-stage kidney disease patients after a waiting period. Any change in the bundled payment rate, add-on adjustments, or value-based models such as Comprehensive Kidney Care Contracting can move revenue and margins.

Commercial payor pricing is equally important. The 10-K explicitly notes that nearly all non-hospital dialysis profit comes from commercial payors, so the spread between commercial rates and lower Medicare rates is what funds the business. Labor market pressure is another sector-wide factor; dialysis centers require nurses, technicians, and trained clinical staff, and wage inflation or staffing shortages can pressure facility-level costs. Because the company operates in 14 countries, it also faces currency translation, foreign regulatory, and jurisdictional reimbursement risks. Finally, care-facility operators are operationally exposed to public health emergencies and natural disasters; with patients needing life-sustaining treatment on fixed schedules, hurricanes, pandemics, or supply-chain disruptions can force costly emergency responses.

Recent Developments

The most recent news cluster came on October 9, 2026. Zacks published “Why DaVita HealthCare (DVA) Outpaced the Stock Market Today” and “Here’s Why You Should Retain DaVita Stock in Your Portfolio for Now,” while Seeking Alpha ran “DaVita: After A 25% Drop, The Buyback Machine Is Cheap Again.” The common thread across these headlines is post-pullback attention: after a roughly 25% decline, sell-side and contributor commentary was focused on whether the valuation had reset enough to make the company’s buyback-supported return-of-capital story look more attractive again.

One day earlier, on October 8, 2026, DaVita issued a press release via PR Newswire announcing that it had activated emergency response efforts ahead of Hurricane Isaias and was urging kidney patients to prepare early. That release underscores the operational reality of running a dialysis network: treatment cannot be deferred, so weather events create direct logistical obligations and potential near-period cost impacts.

Earnings Behavior & Post-Earnings Drift

Over the last eight reported quarters, DaVita has beaten the market’s real expectation six times, for a 75% beat rate, with an average earnings surprise of 2.3%. The average five-day price move after earnings across those quarters is 6.36% to the upside, which suggests a positive post-earnings drift at a high level.

But the more instructive story is the dispersion beneath those averages. The last four reports make the point clearly. On August 4, 2026, DaVita reported $4.02 per share versus the $3.88 estimate, a 3.6% positive surprise—and the stock fell 17.24% the next day and 21.78% over the following five days. That is a beat followed by a severe drawdown. By contrast, the May 5, 2026 quarter delivered $2.87 versus $2.41, a 19.1% beat, and the stock rose 23.46% the next day and 27.7% over the next five sessions. The February 2, 2026 quarter, with $3.40 versus $3.24 (4.9% beat), produced a 21.17% next-day jump and a 23.79% five-day gain. The miss, reported October 29, 2025—$2.51 versus $3.17, a -20.8% surprise—led to a 6.17% next-day drop and a 4.27% five-day decline.

Those figures illustrate the disconnect noted in the data: a beat does not guarantee the post-earnings drift will continue in the direction of the surprise. DaVita’s next scheduled report is October 28, 2026 after the close, with the unofficial consensus EPS estimate at $3.57. Traders interpreting the 75% beat rate as a reliable directional signal should consider that forward guidance, payer-mix commentary, and headline risk can override the headline EPS print.

For a deeper dive into the full institutional verdict on DaVita—including consensus revenue assumptions, rating distributions, and forward estimate revisions—view the complete analyst coverage summary on the platform.